Mumbai: Soon after the inspection of its facility in Madhya Pradesh, the Mumbai-based, Lupin Ltd recently got a couple of key observations for it’s Goa facility from the United States Food and Drug Administration (USFDA). The US health regulator has completed the inspection of its Goa Facility with two observations.
Drug firm Lupin on Friday said the US health regulator has completed the inspection of its Goa facility and made two key observations.
In a BSE filing, Lupin said, “The observations are procedural in nature and the company is confident of addressing them satisfactorily.”
Also Read: Lupin gets 22 observations for MP plant
The United States Food and Drug Administration (USFDA) had carried out the inspection at the Goa manufacturing facility between January 28 and February 8 of this year, it said.
The inspection at the Goa facility closed with two observations, it added.
The company, however, did not disclose the details of observations made by the USFDA.
Lupin was founded in 1968 by Desh Bandhu Gupta. The company’s key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.